Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 4/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23725496 | 0.89 | KDR (0.32) | KDRFGFR3 | |
| SCHEMBL23725575 | 0.89 | HCAR1 (0.33) | HCAR1KDRFGFR3FGFR4FLT3 | |
| SCHEMBL23725935 | 0.87 | KDR (0.33) | KDRFGFR3FGFR4FLT3 | |
| SCHEMBL23725552 | 0.84 | FLT3 (0.32) | KDRFGFR3FLT3 | |
| SCHEMBL23725024 | 0.83 | GABRA1 (0.33) | FLT3 | |
| SCHEMBL23725586 | 0.82 | KDM4E (0.32) | KDRFLT3 | |
| SCHEMBL27080174 | 0.81 | PIK3CA (0.33) | KDRFGFR3 | |
| SCHEMBL23726687 | 0.80 | FGFR3 (0.32) | KDRFGFR3FGFR4FLT3 | |
| SCHEMBL23726188 | 0.80 | FLT3 (0.34) | KDRFGFR3FLT3NPC1 | |
| SCHEMBL23725800 | 0.79 | KDM4E (0.33) | KDRFGFR3FGFR4FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4100381-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-12-14 | — | — | EP | disclosed |
| CN-115413275-A | Substituted 1,1 , -biphenyl compounds and methods of use thereof | 爱彼特生物制药公司 | 2022-11-29 | — | — | CN | disclosed |
| WO-2021158481-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | HCAR1 862/4885KDR 3652/4885FGFR3 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.